8-K: Longeveron HLHS Trial Shows Secondary Endpoint Success

Longeveron Inc. announced updated results from its ELPIS II Phase 2b clinical trial for hypoplastic left heart syndrome (HLHS), where the investigational therapy laromestrocel showed a statistically significant reduction in major adverse cardiac events (MACE) despite not meeting the primary efficacy endpoint.

Summary

• Longeveron Inc. has released updated results from its ELPIS II Phase 2b clinical trial for infants with hypoplastic left heart syndrome (HLHS).
• The trial evaluated laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants.
• While the primary endpoint of change in right ventricular ejection fraction (RVEF) at Month 12 was not met, a pre-specified secondary endpoint, major adverse cardiac events (MACE), achieved statistical significance.
• The laromestrocel arm had 1 MACE event compared to 8 in the standard of care (SOC) arm (P=0.043).
• Laromestrocel was associated with fewer adjudicated clinical and safety events overall compared to the SOC arm.
• The company plans to request a meeting with the FDA to discuss potential next steps for the HLHS development program.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed result, with a statistically significant secondary endpoint but a failure to meet the primary efficacy endpoint, indicating potential but also significant challenges.

Positives

• Achieved statistical significance in a pre-specified secondary endpoint for Major Adverse Cardiac Events (MACE), with 1 event in the laromestrocel arm versus 8 in the standard of care arm (P=0.043).
• Laromestrocel was associated with fewer adjudicated clinical and safety events overall compared to the standard of care arm.
• Laromestrocel demonstrated a favorable safety and tolerability profile through 12 months, with no treatment-related serious adverse events identified.
• The data from the ELPIS II trial has been selected for a Late-Breaking Science Program podium presentation at the American Heart Associations (AHA) 2026 Scientific Sessions.

Negatives

• The primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12 was not met.
• Mean RVEF decreased in both the SOC and Laromestrocel groups, with no statistically significant difference between the two groups after baseline adjustment.

Risks

• The primary efficacy endpoint was not met, which could impact regulatory approval pathways.
• The FDA has previously advised that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other important factors that could cause actual results to differ materially from those anticipated.

Future Outlook

The company intends to request a meeting with the FDA to review the ELPIS II results and determine potential next steps for the HLHS development program. Long-term follow-up for transplant-free survival in the ELPIS II trial is planned for up to 5 years.

Management Comments

• The Company believes the favorable pre-specified secondary endpoint findings suggest that laromestrocel has the potential to meaningfully improve clinical outcomes of children with HLHS undergoing Stage II surgical palliation.
• The Company thanks the patients, families, investigators, and clinical sites who participated in the ELPIS II trial, as well as the NIH and the Data Coordinating and Clinical Coordinating Centers for their partnership throughout the study.

Industry Context

StockSavvy.ai notes that the development of cellular therapies for rare pediatric conditions like HLHS is a high-risk, high-reward area. While the failure to meet primary endpoints is a setback, achieving statistical significance in a critical secondary endpoint like MACE is a positive signal that may warrant further investigation and discussion with regulatory bodies, especially given the significant unmet need in HLHS treatment.

Stakeholder Impact

• Shareholders: The mixed results may lead to uncertainty regarding the future development and potential approval of laromestrocel for HLHS, potentially impacting stock valuation.
• Patients and Families: The potential for laromestrocel to improve clinical outcomes, as suggested by secondary endpoints, offers hope for improved treatment options for infants with HLHS.
• Healthcare Providers: The data may inform treatment decisions and highlight areas for further research in HLHS management.

Next Steps

• Request a meeting with the U.S. Food and Drug Administration (FDA) to review the ELPIS II results.
• Determine potential next steps for the Company's HLHS development program.
• Present ELPIS II Phase 2b trial data at the American Heart Associations (AHA) 2026 Scientific Sessions.
• Continue long-term follow-up for transplant-free survival for up to 5 years for ELPIS II trial participants.

Key Dates

Recommendation

The company failed to meet its primary endpoint, which is a significant negative. However, the statistically significant improvement in MACE and overall fewer clinical/safety events in the treatment arm suggest potential therapeutic benefit. This mixed outcome warrants a 'hold' recommendation, pending further discussions with the FDA and a clearer understanding of the path forward, rather than a definitive buy or sell.

Keywords

laromestrocel, HLHS, hypoplastic left heart syndrome, cellular therapy, pediatric, clinical trial, MACE, RVEF